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ORIGINAL RESEARCH

End-of-Life Healthcare Use of Medicare Patients with
Melanoma Based on Patient Characteristics and Year of
Death
Rebecca N. Hutchinson, MD, MPH, FACP,1 F. Lee Lucas, RN, MS, PhD,1 Kathleen M. Fairfield, MD, MPH,
DrPH1,2
1
Center for Outcomes Research and Evaluation , Maine Medical Center, Portland, ME, 2Department of Medicine, Maine
Medical Center, Portland, ME

Introduction:

Many cancer patients receive overly intensive care at end-of-life (EOL). There is limited knowledge
about care received by patients dying with melanoma. We assessed healthcare use during EOL, patient
characteristics associated with differences in care, and how healthcare use changed over time.

Methods:

We used the Surveillance, Epidemiology, and End Results-Medicare database to identify melanoma
patients aged 65 years and older at diagnosis between 2000 and 2009, and who died by December 31,
2010. We included patients enrolled in Medicare part A and B six-months before diagnosis and not in
managed care for the last 30 days of life. We examined use patterns during the last month of life.

Results:

Among 9099 patients dying with melanoma, 5% had two or more emergency department visits, 3%
had two or more hospitalizations, and 5% had one stay in the intensive care unit during their last
month of life; 7.5% died in the hospital, and 2% received chemotherapy during their last two weeks of
life. Multivariable analysis revealed that patients who were married, male, or with a higher comorbidity
burden received higher intensity EOL care. Temporal analysis revealed a doubling in the number of
patients with multiple hospitalizations (4% vs 2%), emergency department visits (6% vs 3%), and care
in the intensive care unit (7% vs 3%) between 2001 and 2010.

Conclusions:

Patients with melanoma in the United States are receiving EOL care that meets or exceeds benchmarks.
They are also increasing their healthcare use during EOL.

Keywords:
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O

Forum as markers of quality EOL care.8 However,
little is known about EOL care received by patients
dying with melanoma, despite the high prevalence
and increasing incidence of the disease.9
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National studies of patients dying from other
malignancies revealed significant differences
in the intensity of EOL care based on treatment
region, race, age, gender, rurality, marital status,
underlying comorbidities, and sociodemographic
characteristics.7,10-16 One prior study which included
patients with both non-small-cell and small-cell lung
cancer found healthcare utilization at end-of-life
correlated with the underlying malignancy.17 Only a
few studies looked at EOL care received by patients
with melanoma. These studies were either smaller
samples and/or did not include the full range of EOL
care measures recognized as important quality

verly intensive care at end-of-life (EOL) does
not improve survival1,2 and harms patients
and families.3,4 In a series of seminal papers,
Earle and others worked with patients, oncologists,
and other stakeholders to define markers that would
indicate overly intensive care and poor quality EOL
care.5-7 Indicators of inappropriately intense care
included frequent hospitalization and/or emergency
department (ED) visits, admission to the intensive
care unit (ICU), receipt of chemotherapy at EOL,
and dying in the hospital. Benchmarks were
established based on observational studies and
have since been accepted by the National Quality
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markers. Hillner and others reported a consecutive
series of cases treated at one cancer center that
had incomplete EOL data. They found relatively
infrequent hospitalizations and low rates of dying
in the hospital.18 Another study described high
rates of chemotherapy, hospitalization, and dying
in the hospital for melanoma patients in France.19
In the Surveillance, Epidemiology, and End Results
(SEER)-Medicare database, the economic burden
for EOL care was high for patients dying with
melanoma between 1991 and 1996.20 Finally, Huo
and others described rates of hospice, surgery,
radiation therapy, and chemotherapy for patients
with metastatic melanoma. They found that surgery
and hospice use increased over time, with stable
rates of chemotherapy and radiation therapy.21 We
recently reported that rates of hospice enrollment
increased over time for patients dying with
melanoma but remained under accepted quality
benchmarks. We also found notable differences in
hospice receipt based on patient characteristics.23
However, none of these studies used national
data to fully characterize EOL care, including
hospitalizations, ED visits, and ICU admissions.
Although some studies reported increasing rates
of healthcare use at EOL for other diseases and
malignancies, they did not assess whether this
trend also occurs for melanoma.11,24,25
Overall, EOL care for patients dying with melanoma
has been relatively understudied compared
with other malignancies. Understanding these
differences is important to designing interventions
that successfully improve the quality of EOL care.
We sought to identify the intensity of EOL care
received by older patients dying with melanoma,
describe patient characteristics associated with
higher rates of healthcare use, and define how EOL
care for melanoma patients has changed over time.

METHODS
Study design and data sources
Our study design was a retrospective cohort analysis
using data from the linkage of the Surveillance,
Epidemiology, and End Results (SEER) registries
with Medicare claims data.28 An estimated 97% of
incident cases are captured by cancer registries
within SEER regions27 that represent the US
population.28 SEER registries include data on age at
diagnosis, sex, race/ethnicity, marital status, and date
and cause of death for each reported malignancy.26
Cause of death is determined by information on
https://knowledgeconnection.mainehealth.org/jmmc/vol2/iss1/2
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the death certificate.26 Sociodemographic data,
including education, income and rurality, are
assigned to cases at the Census tract-level based
on the 2000 Census. Medicare data include claims
for hospitalizations, ED visits, ICU stays, and
chemotherapy administration for patients enrolled
in fee-for-service Medicare (both Part A and Part B).
Periodically, SEER and Medicare data are linked for
research purposes, with a match rate of 94%.29 Our
data included claims from January 1, 1999 through
December 31, 2010 for melanoma cancer cases
diagnosed between 2000 and 2009. Approval was
obtained from the IRB at Maine Medical Center.
SEER-Medicare data are de-identified and do not
require informed consent.
Cohort definition
The cohort included patients diagnosed with
pathologically confirmed melanoma and age 65
and older between 2000 and 2009 (inclusive) while
living in a SEER area. Patients were enrolled in
Medicare A and B for six months before diagnosis to
calculate a Charlson Comorbidity Score. To obtain
complete data on resource use, we included only
patients who were enrolled in Medicare A and B for
the last 30 days of life. We excluded 365 patients
without pathologically confirmed disease or disease
diagnosed at time of death, as well as 58,814
patients who did not die from cancer during the
period of observation (before December 31, 2010).
In the cohort, 9,099 patients remained available for
analysis. Death certificate data is imprecise,26 so
we included all melanoma patients who died of any
cancer to maximize our statistical power. We then
performed a sensitivity analysis on the subset of
patients who had melanoma definitively identified
as a cause of death (n = 4,780).
Patient characteristics
Patients were categorized based on years of age at
diagnosis (65-69, 70-74, 75-79, 80-84, ≥85). Race
was defined as black, white, and “other” (Hispanic,
Asian, Native American, or Other). Marital status
was defined as married (included domestic partners)
or not married. The American Joint Committee on
Cancer classification, as reported in the SEER
records, were used to determine disease stage
at the time of diagnosis. Rurality was categorized
into the following groups of population density:
≥250,000, 20,000-249,999, 2500-19,999, <2500.
US census data for median household income and
educational attainment were used as proxies for
socioeconomic status. State Buy-In, which indicates
2
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whether the state contributes to a beneficiary’s
Medicare premiums, was included as a proxy for an
individual’s lower socioeconomic status.30 Charlson
Comorbidity Score was calculated on all patients
using claims submitted during the six months before
diagnosis.31
Outcomes
For the analysis, five outcomes accepted as markers
for high quality EOL care for cancer patients were
used.5,8,32 Three outcomes are related to healthcare
use in the last 30 days of life: ≥2 ED visits, ≥2
hospitalizations, and any ICU stay. The time period
for receipt of chemotherapy was the last 14 days.
We also examined inpatient deaths and changes
in each of the healthcare use outcomes over the
study period.
Statistical analysis
All data were analyzed using SAS 9.3 (SAS Institute).
We used chi-square tests and student’s t-tests to
compare proportions and continuous variables as
appropriate. Separate logistic regression models
were developed for each of the five outcomes to
obtain odds ratios (ORs) for predictors of interest.
The models included the following predictors: age
(categorical), gender, tumor stage at diagnosis,
race, marital status, Charlson Comorbidity Score,
rurality, and census tract variables for median
household income and education.

RESULTS
Cohort description
The SEER-Medicare database contained 136,969
cases of melanoma diagnosed between 2000 and
2009. Of these, 69,572 were >65 years old at the
time of diagnosis and were enrolled in Medicare A
and B for six months before diagnosis (necessary to
calculate the Charlson Comorbidity Score). Another
60,473 were excluded because they did not have
pathologically confirmed melanoma before time
of death, were still alive at the end of the study
period, died of a cause other than cancer, or were
not enrolled in fee-for-service Medicare during their
last month of life. The final cohort contained 9,099
patients.
Most patients were 75 years old or older (65%),
male (69%), married or had a domestic partner
(64%), white (98%), lived in a densely populated
area (73%), and came from census tracts with a
median household income over $30,000 (88%)
Published by MaineHealth Knowledge Connection, 2020

(Table 1). Nine percent of the cohort received
State Buy-In. Fourteen percent of the cohort had a
Charlson Comorbidity Score of two or higher.
Intensity of EOL care analyses
Analysis of health care use revealed that 5% of
patients had ≥2 ED visits, 3% had ≥2 hospitalizations,
and 5% had an ICU admission during their last
month of life (Table 2). Two percent of the patients
received chemotherapy in the last two weeks of life,
and 8% died in the hospital.
We noticed differences in the types of patients
who received more intensive care at EOL (Table
2). Patients 85 years old and older were less
likely to receive overly intensive care at EOL on all
measures, though these differences were small.
Patients with a Charlson Comorbidity Score of ≥2
at the time of diagnosis were more likely to have
ED visits (7% vs 5%, P < .0001), hospitalizations
(4% vs 3%, P = .002), and ICU stays (8% vs 5%,
P < .0001) at EOL compared to patients with fewer
comorbidities. They were also more likely to die in
the hospital (9% vs 7%, P = .001). Males were more
likely than females to have higher healthcare use
at EOL, as indicated by higher rates of ED visits
(6% vs 4%, P = .002) and hospitalizations (3% vs
2%, P = .007). Patients residing in more rural areas
were less likely to receive chemotherapy. Finally,
there were differences based on sociodemographic
characteristics: State Buy-In was associated with a
lower rate of in-hospital death (5% vs 8%, P = .01),
and residing in a census tract with lower rates of
high school completion was associated with higher
rates of ED visits (6% vs 4%, P = .04).
Multivariable analysis
Multivariable models revealed that differences in
EOL care persisted based on gender, age, and
marital status after adjusting for other factors
(Table 3). Male patients were more likely to have
≥2 ED visits (OR 1.33; 95% CI 1.04 to 1.71) and
≥2 hospitalizations (OR 1.55; 95% CI 1.10 to 2.19)
during EOL compared with female patients. Older
patients were less likely to receive chemotherapy
compared with the youngest age group (OR 0.46;
95% CI 0.22 to 0.95). Patients with higher Charlson
Comorbidity Scores at the time of diagnosis were
more likely to have higher healthcare use on all
measures except chemotherapy (Table 3).
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Table 1. Characteristics of Patients (n=9099)
Characteristic
Age group, years
66-69
70-74
75-79
80-84
85 ≤
Gender
Female
Male
Race
White
Black
Other
Married
No
Yes
Stage at Diagnosis
Not staged/ missing
In situ
Local
Regional
Distant
Charlson Comorbidity Index
0-1
2≤
Urban/rural residence
250,000 ≤
20,000-249,999
2500-19999
<2500
State Buy-in at death
No
Yes
Education for census tract
>20% fewer than 12 yrs
10-20% fewer than 12 yrs
0-10% fewer than 12 yrs
Median income of zip code for census tract
≤$30,000
>$30,000

https://knowledgeconnection.mainehealth.org/jmmc/vol2/iss1/2
DOI: 10.46804/2641-2225.1030

Number

Percent

1319
1876
2199
2014
1691

14%
21%
24%
22%
19%

2839
6260

31%
69%

8892
78
116

98%
1%
1%

2780
4882

36%
64%

2549
1231
2819
1252
1248

28%
13%
31%
14%
14%

7860
1239

86%
14%

6669
1501
732
196

73%
17%
8%
2%

8279
820

91%
9%

2764
2912
3031

32%
33%
35%

991
7457

12%
88%
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Table 2. Unadjusted Intensity of Care According to Patient Baseline Characteristics Among Decedents (n=9099)∂
Hutchinson Chemotherapy
et al.: EOL Healthcare
Use of≥Medicare
Patients with Melanoma
≥ 2 ED Visits
in
2 Hospitalizations
ICU Stay Within
in Last Month
n (%)

Overall
Benchmark5

P Value

Last 2 Weeks
n (%)

P Value

in Last Month
n (%)

P Value

Last Month
n (%)

462 (5%)

168 (2%)

265 (3%)

494 (5%)

≤ 4%

≤ 10%

≤ 4%

≤ 4%

0.03

Age group, years

0.003

<0.0001

P Value

Died in Hospital
n (%)
681 (8%)
< 17%

0.0002

0.03

66-69

59 (5%)

33 (3%)

35 (3%)

65 (5%)

74 (6%)

70-74

120 (6%)

51 (3%)

69 (4%)

114 (6%)

160 (9%)

75-79

116 (5%)

48 (2%)

78 (4%)

139 (6%)

199 (9%)

80-84

96 (5%)

22 (1%)

54 (3%)

104 (5%)

143 (7%)

85 ≤

71 (4%)

Gender

14 (1%)
0.002

29 (2%)
0.41

72 (4%)
0.007

105 (6%)
0.25

0.07

Female

114 (4%)

47 (2%)

62 (2%)

142 (5%)

191 (7%)

Male

348 (6%)

121 (2%)

203 (3%)

352 (6%)

490 (8%)

Race

NR

Married
No

144 (5%)

Yes

243 (5%)

Stage at Diagnosis
Not staged/ missing

0.79

NR

0.74

0.13

NR

0.02
37 (1%)

81 (3%)

104 (2%)
0.09

0.94

NR

0.64

0.02

NR

0.11
132 (5%)

132 (3%)
0.001

377 (8%)
0.003

0.002

120 (5%)

41 (2%)

72 (3%)

146 (6%)

204 (8%)

In situ

79 (6%)

37 (3%)

51 (4%)

92 (8%)

118 (10%)

Local

127 (5%)

36 (1%)

71 (3%)

125 (4%)

176 (6%)

Regional

69 (6%)

23 (2%)

33 (3%)

67 (5%)

84 (7%)

Distant

67 (5%)

Charlson Comorbidity Index

31 (3%)
<0.0001

38 (3%)
0.29

64 (5%)
0.002

343 (5%)

144 (2%)

199 (3%)

373 (5%)

2≤

119 (7%)

24 (2%)

66 (4%)

121 (8%)

Urban/Rural Residence
250,000 ≤

0.27

0.03

99 (8%)
<0.0001

0-1

0.10

0.001
529 (7%)
152 (9%)

0.93

0.50

332 (5%)

197 (3%)

359 (5%)

494 (7%)

20,000 to 249,999

90 (6%)

37 (3%)

85 (6%)

115 (8%)

2500 to 19,999

31 (4%)

Less than 2500

NR

State Buy-In at death

NR

1.00

No

420 (5%)

Yes

42 (5%)

Education for census tract

20 (3%)

38 (5%)

52 (7%)

11 (6%)

12 (6%)

20 (10%)

0.47
156 (2%)
12 (2%)

0.04

0.60
244 (3%)

0.05
462 (6%)

21 (3%)
0.13

0.01
638 (8%)

32 (4%)
0.15

43 (5%)
0.75

0.07

>20% fewer than 12 yrs

156 (6%)

41 (2%)

83 (3%)

158 (6%)

232 (8%)

10-20% fewer than 12 yrs

156 (5%)

55 (2%)

99 (3%)

153 (5%)

219 (8%)

0-10% fewer than 12 yrs

129 (4%)

Median income of zip code for census
tract, tertiles

67 (2%)
0.60

77 (3%)
0.04

166 (6%)
0.35

0.63
0.09

185 (7%)

275 (6%)
0.07

P Value

206 (7%)
1.00

0.99

>$30,000

373 (5%)

149 (2%)

225 (3%)

410 (6%)

567 (8%)

≤$30,000

54 (6%)

NR

24 (2%)

55 (6%)

76 (8%)

Cells with n < 11 are suppressed per SEER-Medicare policy. ED, emergency department; ICU, intensive care unit; NR, no result.
∂
The percent
in each column
represents the
proportion of
patients with each characteristic who had the outcome of interest compared to those who did not have the outcome.
Published
by MaineHealth
Knowledge
Connection,
2020
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Table 3. Multivariable Adjusted Intensity of Care According
Patient
Baseline
Characteristics
Decedents
(n=9099), ORs (95% CI)Ω
Journal oftoMaine
Medical
Center,
Vol. 2 [2020], Among
Iss. 1, Art.
2
≥2 ED Visits in Last
Month of Life

Received Chemotherapy <14
days Before Death

>2 Hospitalizations in
Last Month of Life

ICU Stay Within Last
Month of Life

Died in Hospital

Age group, years
66-69

1.00 Referent

1.00 Referent

1.00 Referent

1.00 Referent

1.00 Referent

70-74

1.46 (1.04, 2.06)

1.22 (0.73, 2.04)

1.41 (0.89, 2.22)

1.28 (0.90, 1.81)

1.61 (1.18, 2.21)

75-79

1.10 (0.78, 1.56)

1.05 (0.62, 1.76)

1.24 (0.79, 1.97)

1.30 (0.92, 1.82)

1.64(1.20, 2.23)

80-84

0.91 (0.63, 1.32)

0.56 (0.30, 1.04)

0.93 (0.57, 1.53)

0.92 (0.63, 1.33)

1.26 (0.91, 1.76)

85 ≤

0.70 (0.46, 1.06)

0.46 (0.22, 0.95)

0.58 (0.33, 1.05)

0.91 (0.61, 1.35)

1.20 (0.85, 1.71)

1.00 Referent

1.00 Referent

1.00 Referent

1.00 Referent

1.00 Referent

1.33 (1.04, 1.71)

1.00 (0.67, 1.48)

1.55 (1.10, 2.19)

1.07 (0.84, 1.36)

1.13 (0.92, 1.38)

Gender
Female
Male
Race
1.00 Referent

1.00 Referent

1.00 Referent

1.00 Referent

1.00 Referent

Black

White

0.52 (0.13, 2.16)

1.15 (0.15, 8.65)

1.16 (0.28, 4.89)

0.83 (0.26, 2.70)

1.34 (0.57, 3.19)

Other

1.18 (0.54, 2.60)

2.16 (0.77, 6.07)

0.68 (0.16, 2.79)

0.17 (0.02, 1.20)

0.77 (0.33, 1.77)

Married
No

1.00 Referent

1.00 Referent

1.00 Referent

1.00 Referent

1.00 Referent

Yes

0.84 (0.66, 1.06)

1.40 (0.93, 2.12)

0.71 (0.52, 0.96)

1.06 (0.84, 1.35)

1.07 (0.87, 1.31)

Stage at diagnosis
Not staged/ missing

0.76 (0.53, 1.10)

0.46 (0.27, 0.78)

0.86 (0.53, 1.39)

0.91 (0.65, 1.29)

0.81 (0.61, 1.09)

In situ

1.00 Referent

1.00 Referent

1.00 Referent

1.00 Referent

1.00 Referent

Local

0.76 (0.53, 1.08)

0.37 (0.22, 0.64)

0.72 (0.45, 1.16)

0.68 (0.48, 0.96)

0.63 (0.47, 0.85)

Regional

0.94 (0.64, 1.39)

0.60 (0.34, 1.06)

0.83 (0.49, 1.41)

0.84 (0.57, 1.24)

0.71 (0.51, 0.99)

Distant

0.85 (0.58, 1.26)

0.76 (0.45, 1.31)

0.91 (0.54, 1.53)

0.82 (0.56, 1.21)

0.84 (0.61, 1.16)

Charlson Comorbidity Index
0-1

1.00 Referent

1.00 Referent

1.00 Referent

1.00 Referent

1.00 Referent

2≤

1.99 (1.54, 2.57)

0.88 (0.55, 1.44)

1.63 (1.14, 2.33)

1.89 (1.46, 2.43)

1.78 (1.43, 2.23)

1.00 Referent

1.00 Referent

1.00 Referent

1.00 Referent

1.00 Referent

20,000 to 249,999

1.21 (0.93, 1.59)

0.62 (0.36, 1.08)

0.74 (0.48, 1.14)

1.18 (0.90, 1.56)

0.95 (0.74, 1.22)

2500 to 19,999

0.68 (0.42, 1.09)

0.73 (0.32, 1.63)

0.96 (0.54, 1.69)

1.09 (0.73, 1.65)

0.97 (0.68, 1.39)

< 2500

1.27 (0.65, 2.49)

NR

2.32 (1.12, 4.78)

1.61 (0.86, 3.00)

1.48 (0.86, 2.56)

>20% fewer than 12 yrs

1.00 Referent

1.00 Referent

1.00 Referent

1.00 Referent

1.00 Referent

10-20% fewer than 12 yrs

0.94 (0.71, 1.24)

1.29 (0.77, 2.14)

1.24 (0.85, 1.80)

0.86 (0.65, 1.13)

0.86 (0.68, 1.09)

0-10% fewer than 12 yrs

0.78 (0.58, 1.06)

1.32 (0.79, 2.21)

0.81 (0.54, 1.24)

0.89 (0.67, 1.19)

0.76 (0.59, 0.98)

>$30,000

1.00 Referent

1.00 Referent

1.00 Referent

1.00 Referent

1.00 Referent

≤ $30,000

1.03 (0.71, 1.48)

0.81 (0.37, 1.75)

0.78 (0.45, 1.34)

0.93 (0.65, 1.35)

0.80 (0.58, 1.11)

Urban/rural residence
250,000 ≤

Education for census tract

Median income of zip code for census tract

https://knowledgeconnection.mainehealth.org/jmmc/vol2/iss1/2
Cells with n < 11 are suppressed per SEER-Medicare policy. ED, emergency department; ICU, intensive care unit; NR, no result; OR, odds ratio.
DOI: 10.46804/2641-2225.1030
Ω Odds ratios presented in each column are the result of separate logistic regression models for each outcome.
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Sensitivity analysis
Given the imprecise nature of death certificate
data,26 our primary analysis included all patients
who died of cancer. Sensitivity analysis with the
cohort of patients with melanoma specified as the
cause of death revealed similar results in direction
and magnitude. However, some of the findings
were not statistically significant due to reduced
power from a smaller sample size.
Temporal trends
Over time, we observed a doubling in the rates
of patients having ≥2 ED visits (3% of those who
died in 2001 vs 6% in 2010, P trend = .0005) and
in having ≥2 hospitalizations (2% of those who died
in 2001 vs 4% in 2010, P trend = .007) (Figure 1).
More than twice as many patients who died in 2010
had an ICU stay compared to those who died in
2001 (7% vs 3%; P trend < .0001). There were no
temporal changes in rates of in-hospital death or
receipt of chemotherapy during the study period.

DISCUSSION
Our study is the first to use national data of patients
with melanoma to describe EOL care received
using accepted indicators of quality of care.5-8,32 We
found modest differences in healthcare use based
on sex, marital status, and comorbidities. Overall,
patients dying with melanoma met or exceeded the
accepted benchmarks for late chemotherapy (2%
vs benchmark of ≤10%), hospitalizations (3% vs
benchmark of ≤4%), and dying in the hospital (8%
vs benchmark of <17%).6 In contrast, we found a
slightly higher rate of ED visits (5% vs benchmark
of ≤4%) and receipt of ICU care (5% vs benchmark
of ≤4%) during EOL. We also observed a trend of
increasingly intensive care over time. By the last
year of our study, the rate of ICU care reached
nearly twice the accepted benchmark. These
findings complement and extend our prior finding
that 40% of melanoma patients received hospice
care, of which 17% were enrolled within three days
of death.
Our results extend the current understanding of
EOL care received by patients dying with melanoma
from a national perspective. A recent study also
used the SEER-Medicare database to characterize
receipt of chemotherapy, surgery, and radiation
therapy at EOL for patients diagnosed with stage
IV melanoma. We did not limit our cohort based
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on stage at diagnosis. Similar to our findings, they
observed that older and unmarried patients were
less likely to receive chemotherapy.21 Another
study looked at EOL care received by patients
with melanoma and found relatively infrequent
hospitalizations at EOL. However, this study used
a series of consecutive cases treated at a referral
cancer center and lacked complete data on as many
as 40% of patients who received EOL care closer to
home.18 A French study found much higher intensity
EOL care than we observed, including as many as
20% of patients being hospitalized continuously
during their last month of life. The difference in
intensity may be due to cultural differences between
France and the US, as well as the availability
of hospice services.20 Another study described
EOL care received by melanoma patients in the
20% Medicare Denominator file and included all
patients dying with poor-prognosis cancers. They
noted much higher rates of healthcare use on all
measures than we observed.10
Our study extends previous findings on the intensity
of EOL care for patients dying with melanoma by
using national data and including more years and
wider inclusion criteria. These data improve the
generalizability of our findings. Furthermore, our
analysis included State Buy-In, an individual marker
of low socioeconomic status. Our study included
multiple indicators of quality EOL care that were not
included in any prior national study for melanoma
patients. The time-period included in our analysis
also revealed how EOL care received by melanoma
patients is changing over time.
We found multiple patient characteristics that were
associated with slightly higher healthcare use at
EOL for patients dying with melanoma, including
male sex and being married. Although no prior
studies commented on the association of these
characteristics in melanoma patients, studies of
other cancers found similar patterns.7,10-11,15 A recent
study showed that male patients were less likely
to prefer palliative care, defined as care focusing
on “quality of life” and not “cure.” These data
suggest that patient preferences may be driving
the observed differences.16 Other studies linked
psychological and personality characteristics, some
of which may be more common among men, to EOL
preferences.33 Similar to the gender difference, prior
work suggests that married patients may prefer
more intensive care.15
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Older age is associated with lower rates
of
chemotherapy
administration,
as
we
observed.21,23,34,35 Possible explanations include
increased toxicity of chemotherapy for older
patients,36 a recognition of a decrease in likelihood
of benefit,37 or different preferences for care.38 We
found that patients with a higher burden of comorbid
illnesses were more likely to have ED visits,
hospitalizations, or an ICU stay at EOL and to die
in the hospital. These findings support prior studies
of other malignancies,7,11-12 which may be related
to patients with comorbid diseases having different
preferences for EOL care or hospices having
greater difficulty managing sicker patients.39,40
We found that rates of healthcare use during
EOL increased over time for all measures except
chemotherapy administration and dying in the
hospital. These rates were observed in studies
of other malignancies7,11,41,42 and included other
causes of death.24,25 Interestingly, we recently
showed increases in hospice care over time,
which we would expect to decrease measures of
healthcare use during EOL.23 It is likely that receipt
of hospice care is impacting the rate of in-hospital
death most directly, for which we and others have
not seen an increase.26,27 The reasons behind
these increases in burdensome care are unknown
and warrant further study. Notably, although
we observed increases in EOL healthcare use
that surpass many of the benchmarks, the rates
remained substantially below those reported by
studies of other malignancies.2,11,43
Our analysis has several limitations. This study
relies on claims data, so we do not have clinical
data that might explain the observed differences
in EOL care. We cannot assess to what extent our
findings reflect patients’ or providers’ preferences
or are related to differential access to care. Our
primary analysis was on all patients who died of
cancer, which may include melanoma patients
who died from a different malignancy or may have
missed patients who died from melanoma-related
complications that were not identified on their death
certificate. Sensitivity analysis with those who
died definitively of melanomas revealed similar
trends. As a result of our large sample sizes, some
of the comparisons were statistically significant
despite small differences that may not be clinically
meaningful.
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The study period used for this analysis was before
immunotherapy was used widely to treat melanoma.
While immunotherapies have improved the survival
of some patients with melanoma, we do not know
if they alter the experiences of patients dying with
melanoma. In fact, one recent study found increased
variations in care after the advent of bevacizumab
for lung cancer.13 Immunotherapy is generally
better tolerated, which may increase the number of
patients receiving chemotherapy or starting a new
chemotherapeutic regimen at EOL. Furthermore,
experts are concerned that the availability of
immunotherapies has increased prognostic
uncertainty, which may delay conversations about
the goals of care and ultimately lead to more
aggressive care at EOL.44,45 In addition, although
these benchmarks are endorsed by the National
Quality Forum and used in the literature, they may
need to be updated with the changes in cancer
care since their inception, such as the increased
integration of palliative medicine. Finally, while the
SEER registry represents the US population, we
cannot comment on the entire Medicare population
because we are limited to patients residing in the
SEER areas.26

CONCLUSIONS
Our study adds to the increasing evidence base
that some patients receive more intensive and nonbeneficial care at EOL, and that this problem is
worsening over time. Additional research is needed
to better understand what drives this trend. Receipt
of inappropriately intensive EOL care may be
related to prognostication challenges,46-48 physician
reticence in discussing prognosis with patients,49,50
and/or how prognosis and the benefits of intensive
EOL care are presented to patients.50 Earlier
access to palliative-care clinicians and support
for improved communication between melanoma
patients and their physicians may decrease
inappropriately intense EOL care, as shown for
other malignancies.51-54 These services could be
targeted to populations most likely to receive overly
intensive EOL care. Our study demonstrates a need
to better understand how to improve the quality of,
and decrease nonbeneficial, EOL care.
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